New pill hopes to clear stubborn hand and foot blisters
NCT ID NCT07270003
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called ivarmacitinib for palmoplantar pustulosis (PPP), a chronic skin condition causing painful blisters on hands and feet. Sixty adults who haven't improved with other treatments will take the pill for 12 weeks. Researchers will check if symptoms like blisters and redness get at least 50% better, and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivarmacitinib
What this could lead to
If it works, this could offer a new oral treatment option for people with palmoplantar pustulosis who haven't responded to other therapies.
What could go wrong
This is a small, early-stage trial with no control group, so results may not be conclusive. Side effects like infections or stomach issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••